Here is the original post: Renovaro Regains Compliance with NASDAQ Listing Requirement
Here is the original post: Renovaro Regains Compliance with NASDAQ Listing Requirement
Read more: Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
Continue reading here: PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
See the original post here: Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
Read the rest here: Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Read the original: ViGeneron Announces FDA Clearance of IND for Novel mRNA Trans-Splicing Gene Therapy VG801 to Treat Stargardt Disease and Other ABCA4-Linked Retinal...
More here: Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
More: Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
Follow this link: Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
More: Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Recent Comments